Home » Stocks » TBPH

Theravance Biopharma, Inc. (TBPH)

Stock Price: $19.21 USD -0.54 (-2.73%)
Updated May 10, 2021 2:25 PM EDT - Market open
Market Cap 1.29B
Revenue (ttm) 66.25M
Net Income (ttm) -274.64M
Shares Out 65.22M
EPS (ttm) -4.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $19.21
Previous Close $19.75
Change ($) -0.54
Change (%) -2.73%
Day's Open 19.82
Day's Range 19.09 - 19.98
Day's Volume 83,311
52-Week Range 14.48 - 29.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, May 6, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-sele...

4 days ago - PRNewsWire

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

5 days ago - Zacks Investment Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.10% and -18.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 8.77% over the past year to ($1.24), ...

5 days ago - Benzinga

DUBLIN, May 4, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2021. "2021 is on track ...

5 days ago - PRNewsWire

DUBLIN, April 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-s...

2 weeks ago - PRNewsWire

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

DUBLIN, March 2, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-se...

2 months ago - PRNewsWire

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

2 months ago - Zacks Investment Research

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.37% over the past year to ($0.92), whic...

2 months ago - Benzinga

DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-se...

3 months ago - PRNewsWire

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-sel...

3 months ago - PRNewsWire

DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-se...

4 months ago - PRNewsWire

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Today, we revisit Theravance Biopharma for the first time in over a year. The stock has had a challenging year in 2020, but there are some potentially significant catalysts on the horizon in 2021.

5 months ago - Seeking Alpha

Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.

6 months ago - Zacks Investment Research

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.37% and 3.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020....

6 months ago - PRNewsWire

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-se...

6 months ago - PRNewsWire

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, JAZZ, TXAC, TXG
8 months ago - The Motley Fool

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

8 months ago - PRNewsWire

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

9 months ago - Zacks Investment Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

9 months ago - PRNewsWire

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-se...

9 months ago - PRNewsWire

DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, deve...

10 months ago - PRNewsWire

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

10 months ago - Zacks Investment Research

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primari...

10 months ago - PRNewsWire

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

1 year ago - Zacks Investment Research

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Theravance Biopharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 appea...

1 year ago - Investors Business Daily

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

1 year ago - Zacks Investment Research

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.41% and 60.93%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Investors didn't like the drugmaker's pricing of a planned public stock offering.

1 year ago - The Motley Fool

Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

1 year ago - Zacks Investment Research

Despite achieving several milestones over the past two years, the stock’s response has been muted.

1 year ago - The Motley Fool

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

Other stocks mentioned: ABBV, BIIB, INVA, MYL, NVS, REGN
1 year ago - InvestorPlace

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2019 - Earnings Call Transcript

1 year ago - Seeking Alpha

About TBPH

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative coliti... [Read more...]

Industry
Biotechnology
CEO
Rick Winningham
Employees
359
Stock Exchange
NASDAQ
Ticker Symbol
TBPH
Full Company Profile

Financial Performance

In 2020, TBPH's revenue was $71.86 million, a decrease of -2.12% compared to the previous year's $73.41 million. Losses were -$278.02 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is 30.63, which is an increase of 59.45% from the latest price.

Price Target
$30.63
(59.45% upside)
Analyst Consensus: Buy